Drugs / Vitamin B12
Vitamin B12
English name Cyanocobalamin
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | CYANOCOBALAMIN | — | 1997-06-25 | fda.gov ↗ |
| Approved | US (FDA) | BEROCCA PN | — | 1947-07-28 | fda.gov ↗ |
Trials 59
19461947194819491950195119521953195419551956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials · 1 missed | ||||||
| Phase 0 | NCT05330936 | Jan 2021 → Sep 2022 | psoriasis | Pak Emirates Military Hospital | Completed | No outcome recorded |
| Phase 0 | NCT03437824 | Oct 2017 → Apr 2019 | vitamin B12 deficiency | University of Southern California | Completed | Missed primary |
| Phase 13 trials | ||||||
| Phase 1 | NCT04235426 | Jan 2018 → Jan 2021 | carpal tunnel syndrome | Dalia Salah Saif | Unknown | No outcome recorded |
| Phase 1 | NCT01864824 | Jun 2013 → Jul 2014 | — | Harvard School of Public Health (HSPH) | Completed | No outcome recorded |
| Phase 1 | NCT01306123 | Feb → May 2011 | — | Swedish Orphan Biovitrum | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01704599 | Jan 2009 → Jun 2013 | psoriasis | Wayne State University | Terminated | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT06098456 | Nov 2023 → May 2024 | papilloma | Centro di Ricerca Clinica Salentino | Completed | No outcome recorded |
| Phase 2 | NCT03778008 | Dec 2018 → Dec 2019 | stomatitis | Second Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| Phase 2 | NCT02773147 | Apr 2016 → Nov 2018 | HIV infectious disease | Göteborg University | Unknown | No outcome recorded |
| Phase 2 | NCT01490944 | Jan → Nov 2012 | anemia | Indian Council of Medical Research | Unknown | No outcome recorded |
| Phase 2 | NCT00214682 | Oct 2005 → Jan 2011 | depressive disorder | Australian National University | Completed | No outcome recorded |
| Phase 2 | NCT00000541 | May 1993 → Jul 2005 | coronary atherosclerosis, myocardial infarction, myocardial ischemia | Brigham and Women's Hospital | Completed | Missed primary |
| Phase 2/34 trials · 3 missed | ||||||
| Phase 2/3 | NCT05005897 | Dec 2021 → Oct 2025 overdue | vitamin B12 deficiency | Innlandet Hospital Trust | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00202280 | Sep 2004 → Sep 2006 | psychotic disorder | Melbourne Health | Completed | Missed primary |
| Phase 2/3 | NCT00064753 | May 2002 → Oct 2011 | cardiovascular disorder, chronic kidney disease | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Missed primary |
| Phase 2/3 | NCT00114400 | Nov 2000 → Feb 2007 | atherosclerosis | National Institute on Aging (NIA) | Completed | Missed primary |
| Phase 310 trials · 3 missed | ||||||
| Phase 3 | NCT06966856 | Dec 2026 → Dec 2028 expected | vitamin B12 deficiency | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06517823 | Apr → Oct 2024 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT05796401 | Dec 2023 → Dec 2026 expected | psychotic disorder | Centre Hospitalier St Anne | Recruiting | No outcome recorded |
| Phase 3 | NCT05958277 | Jun 2021 → Jan 2023 | traumatic brain injury | KRL Hospital, Islamabad | Completed | No outcome recorded |
| Phase 3 | NCT02007837 | Jan → Apr 2018 | hypertension, pregnancy-induced | UMC Utrecht | Unknown | No outcome recorded |
| Phase 3 | NCT00116493 | Apr 2004 → May 2007 | anemia | Johns Hopkins Bloomberg School of Public Health | Completed | Missed primary |
| Phase 3 | NCT00056225 | Jan 2003 → Jun 2007 | Alzheimer disease | National Institute on Aging (NIA) | Completed | Missed primary |
| Phase 3 | NCT00032435 | May 2001 → Aug 2006 | end stage renal failure, kidney failure | US Department of Veterans Affairs | Completed | Missed primary |
| Phase 3 | NCT00350116 | Jan 2001 → Dec 2004 | psoriasis | Ruhr University of Bochum | Completed | No outcome recorded |
| Phase 3 | NCT00004734 | Sep 1996 → Feb 2004 | cerebral infarction, myocardial infarction | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 49 trials · 2 missed | ||||||
| Phase 4 | NCT07592897 | Jun → Nov 2026 expected | — | University of Sao Paulo | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07523646 | May 2026 → Apr 2028 expected | anemia, infective endocarditis | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| Phase 4 | NCT07029698 | Apr → Oct 2025 | vitamin B12 deficiency | Medice Arzneimittel Pütter GmbH & Co KG | Completed | No outcome recorded |
| Phase 4 | NCT05221892 | Nov 2021 → Mar 2023 | — | Fundação Educacional Serra dos Órgãos | Completed | No outcome recorded |
| Phase 4 | NCT02120274 | Mar 2014 → May 2016 | Flaviviridae infectious disease, chronic hepatitis C virus infection | Federal University of São Paulo | Terminated | No outcome recorded |
| Phase 4 | NCT01832129 | May 2013 → Dec 2015 | vitamin B12 deficiency | University Hospital, Basel, Switzerland | Completed | Missed primary |
| Phase 4 | NCT03221816 | Dec 2008 → Jan 2010 | hyperhomocysteinemia, hyperlipidemia | Casa de Saúde santa Marcelina | Completed | No outcome recorded |
| Phase 4 | NCT00326833 | Jan 2006 → Dec 2010 | vitamin B12 deficiency | University of Aarhus | Unknown | No outcome recorded |
| Phase 4 | NCT00106886 | Dec 1999 → Oct 2005 | cancer, myocardial infarction, stroke disorder | Hamilton Health Sciences Corporation | Unknown | Missed primary |
| Phase not applicable24 trials · 3 missed | ||||||
| — | NCT06749756 | Feb 2025 → Feb 2026 overdue | infectious disease with sepsis | Fan Zeng | Recruiting | No outcome recorded |
| — | NCT06301685 | Mar → Jun 2024 | autism | Muhammad | Unknown | No outcome recorded |
| — | NCT06249490 | Feb → May 2024 | obstructive sleep apnea syndrome | Zeng Changhao | Unknown | No outcome recorded |
| — | NCT04343170 | Sep 2023 → Sep 2024 | idiopathic scoliosis, iron deficiency anemia | Tanta University | Completed | No outcome recorded |
| — | NCT06347250 | Jan 2022 → May 2023 | cranial nerve palsy | Babujinaya Cela | Completed | No outcome recorded |
| — | NCT06042738 | Mar → Nov 2021 | male infertility | Ondokuz Mayıs University | Completed | No outcome recorded |
| — | NCT03802422 | Apr 2019 → Apr 2020 | carpal tunnel syndrome | Tri-Service General Hospital (TSGH) | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT01127724 | Jun 2012 → Oct 2014 | aphthous stomatitis | Meir Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01317849 | Jul 2011 → Jun 2016 | transient ischemic attack | Xijing Hospital | Withdrawn | No outcome recorded Stop: Business |
| — | NCT01474486 | Apr 2010 → Feb 2016 | cardiomyopathy, congestive heart failure | Phoenix VA Health Care System | Completed | No outcome recorded |
| — | NCT01876732 | Jun 2009 → Apr 2011 | vitamin B12 deficiency | Northwell Health | Completed | No outcome recorded |
| — | NCT00901394 | Mar 2009 → Jan 2010 | congenital anomaly of cardiovascular system | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT01311739 | May → Jun 2008 | — | Emisphere Technologies, Inc. | Completed | No outcome recorded |
| — | NCT00655980 | Feb 2008 → Dec 2016 | coronary artery disorder | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00465699 | Apr 2007 | atopic eczema | Spartanburg Regional Healthcare System | Unknown | No outcome recorded |
| — | NCT00843453 | Nov 2006 → Jan 2008 | vitamin B12 deficiency | University of Delaware | Completed | No outcome recorded |
| — | NCT00348933 | Jul 2006 → Feb 2010 | Angelman syndrome | University of California, San Diego | Completed | Missed primary |
| — | NCT00288769 | Mar 2006 → Dec 2007 | aphthous stomatitis | Soroka University Medical Center | Completed | No outcome recorded |
| — | NCT00394862 | Jan → Jun 2006 | neural tube defect | Emory University | Completed | No outcome recorded |
| — | NCT00306358 | May → Oct 2005 | disorder of vitamin and non-protein cofactor absorption and transport | University of Aarhus | Completed | No outcome recorded |
| — | NCT00120484 | Apr 2005 → Dec 2007 | circadian rhythm sleep disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| — | NCT00004495 | Jun 1999 → Sep 2000 | end stage renal failure, hyperhomocysteinemia | Georgetown University | Completed | No outcome recorded |
| — | NCT00266487 | Dec 1998 → Mar 2004 | acute myocardial infarction | University of Tromso | Completed | Missed primary |
| — | NCT00314990 | Jan 1996 → Jan 2003 | pulmonary embolism, venous thromboembolism | Radboud University Medical Center | Completed | Missed primary |
| Comparator or background therapy37 trials | ||||||
| Phase 1 | NCT05426395 Comparator | Jun 2023 → Jan 2024 overdue | vitamin B12 deficiency | George Washington University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05027126 Background | Feb → Nov 2019 | — | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT03101579 Background | Mar 2017 → Sep 2018 | malignant tumor of meninges | The First Hospital of Jilin University | Completed | No outcome recorded |
| Phase 1/2 | NCT05289908 Background | Feb 2022 → Mar 2023 | malignant leptomeningeal tumor | The First Hospital of Jilin University | Completed | No outcome recorded |
| Phase 1/2 | NCT04708340 Comparator | Mar 2021 → Oct 2022 | COVID-19, acute respiratory distress syndrome | Reven Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03887169 Background | Sep 2019 → Jun 2020 | inborn mitochondrial metabolism disorder, pulmonary alveolar proteinosis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1/2 | NCT01188876 Background | Aug 2010 → Jul 2016 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02735317 Comparator | Apr 2016 → Jun 2017 | nasopharyngeal neoplasm, stomatitis | Yun-fei Xia | Unknown | No outcome recorded |
| Phase 2 | NCT02106650 Background | Jul 2014 → Oct 2018 | peripheral T-cell lymphoma, not otherwise specified | Acrotech Biopharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01165021 Background | Nov 2010 → Jul 2013 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01183065 Background | Aug 2010 → Apr 2014 | head and neck cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01194453 Background | Nov 2009 → Sep 2010 | non-small cell lung carcinoma | Sun Yat-sen University | Completed | Missed primary |
| Phase 2 | NCT01490437 Background | Jul 2008 → Dec 2013 | urothelial carcinoma | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00227019 Background | Mar 2006 → Nov 2010 | metastatic neoplasm, non-small cell lung carcinoma | Heather Wakelee | Completed | No outcome recorded |
| Phase 2 | NCT00693589 Comparator | Jan 2005 → Feb 2007 | cardiovascular disorder | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 2 | NCT00243022 Background | Sep 2004 → Mar 2010 | brain edema, central nervous system neoplasm | Ali Altunkaya | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT06516094 Background | Apr 2024 → Jan 2025 | chronic pain syndrome | Laboratorios Silanes S.A. de C.V. | Completed | No outcome recorded |
| Phase 3 | NCT04189367 Background | Jun 2020 → Jul 2022 | burning mouth syndrome | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04197115 Comparator | Sep 2019 → Aug 2020 | infectious disease with sepsis | IMSS Hospital General de Zona 11, Piedras Negras | Completed | No outcome recorded |
| Phase 3 | NCT04085354 Comparator | Feb → Jun 2019 | premature ejaculation | Sohag University | Completed | No outcome recorded |
| Phase 3 | NCT03193788 Background | Jan 2017 → Dec 2019 | transitional cell carcinoma, ureter cancer, urinary bladder cancer | Asan Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT03408639 Background | Jun 2016 → Jul 2017 | aregenerative anemia | Cinnagen | Completed | Met primary |
| Phase 3 | NCT00354081 Comparator | Apr 1999 → Jun 2007 | coronary artery disorder, myocardial infarction, stroke disorder | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT07296354 Comparator | Jan 2026 → Feb 2028 expected | neuropathy, painful | Egyptian International Pharmaceutical Industries Co | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04387201 Background | May 2020 → Oct 2023 | glucose intolerance, obesity disorder | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT04346004 Background | Apr 2020 → Mar 2023 | aortic valve stenosis | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT02640417 Background | Mar 2016 → Mar 2018 | — | Fundação Educacional Serra dos Órgãos | Completed | No outcome recorded |
| Phase 4 | NCT02031289 Comparator | Dec 2013 → Dec 2017 | anemia, disorder of iron metabolism and transport | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT02620345 Background | Jan 2010 → Oct 2015 | benign neoplasm of corpus uteri | Trieu, Nguyen Thi, M.D. | Completed | No outcome recorded |
| — | NCT06319612 Background | Mar → Dec 2024 | obstructive sleep apnea syndrome | Copka Sonpashan | Unknown | No outcome recorded |
| — | NCT06304116 Background | Mar → Jun 2024 | traumatic brain injury | Muhammad | Unknown | No outcome recorded |
| — | NCT06304090 Background | Mar → Dec 2024 | cerebral palsy | Muhammad | Unknown | No outcome recorded |
| — | NCT06255730 Background | Feb → Jun 2024 | insomnia | Zeng Changhao | Unknown | No outcome recorded |
| — | NCT06335316 Background | Jan 2022 → May 2023 | — | Copka Sonpashan | Completed | No outcome recorded |
| — | NCT06176404 Background | Feb 2021 → May 2023 | cerebrovascular disorder, cognitive disorder | Zeng Changhao | Completed | No outcome recorded |
| — | NCT01095211 Comparator | Jan 2003 → Sep 2005 | cognitive disorder | Saarland University | Completed | No outcome recorded |
| — | NCT00097669 Comparator | Nov 1998 → Jun 2009 | transient ischemic attack | VITATOPS | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-07-03 | Lupin Limited | Regulatory Lupin Receives Approval from U.S. FDA for Cyanocobalamin Nasal Spray lupin.com ↗ |
| 2022-04-18 | Zydus Lifesciences Limited | Regulatory Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection zyduslife.com ↗
Zydus Lifesciences Ltd. (Formerly known as Cadila Healthcare Ltd.) has received final approval from the USFDA to market Cyanocobalamin Injection in the strengths of 1,000 mcg/mL,10,000 mcg/10 mL (1,000 mcg/mL), and 30,000 mcg/30 mL (1,000 mcg/mL) Multiple -Dose Vials. |
All press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-12 | Eli Lilly and Company | An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 lilly.com ↗ |
| 2024-02-02 | Lupin Limited | Lupin Launches Cyanocobalamin Nasal Spray in the United States lupin.com ↗ |
| 2023-07-03 | Lupin Limited | Lupin Receives Approval from U.S. FDA for Cyanocobalamin Nasal Spray lupin.com ↗ |
| 2022-12-01 | Meitheal Pharmaceuticals, Inc. | Cyanocobalamin Injection, USP Now Available meithealpharma.com ↗ |
| 2022-04-18 | Zydus Lifesciences Limited | Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection zyduslife.com ↗ |
| 2019-08-21 | Perrigo Company | Perrigo Announces Patent Litigation Settlement for the Generic Version of Nascobal® Nasal Spray perrigo.com ↗ |
| 2019-03-05 | Perrigo Company | Perrigo Confirms Patent Challenge for Generic Version of Nascobal® perrigo.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 104 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vitamin B(12) | “with daily multivitamins [vitamin A (300 microg, as retinol palmitate), vitamin E (6 mg tocopherol equivalents), vitamin B-12 (0.9 microg), vitamin C (15 mg), riboflavin (0.5...” PMID 19535425 ↗ Jun 200976“We randomly assigned 5522 patients 55 years of age or older who had vascular disease or diabetes to daily treatment either with the combination of 2.5 mg of folic acid, 50 mg...” PMID 16531613 ↗ Mar 2006 “We conducted a trial using methylation-promoting dietary supplements (betaine, metafolin, creatine, and vitamin B(12) ) in an attempt to reduce antisense transcript production,...” PMID 22002941 ↗ Oct 2011 “food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg...” NCT06042738 ↗ “Specifically for this study, the methyl donor supplement has been made by Jamieson Laboratories, and consists of 50mg Vitamin B6 and 1 mg Vitamin B12, (both within Health...” NCT01864824 ↗ “Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and...” NCT06304116 ↗ “The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). once a day, 10 days totally.” NCT06319612 ↗ “the patients in the observation group were provided with Stellate Ganglion Block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).” NCT06255730 ↗ “Participants received a daily capsule containing 40 mg of folic acid, 100 mg of pyridoxine hydrochloride (vitamin B6), and 2 mg of cyanocobalamin (vitamin B12) or a placebo.” PMID 17848650 ↗ Sep 2007 “The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).” NCT06304090 ↗ “the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).” NCT06301685 ↗ |
| Known as | B12 | “high-dose folate, vitamin B(6), and vitamin B(12) supplementation” PMID 18854539 ↗ Oct 20086“(2 mg folic acid, 25 mg vitamin B(6), and 500 μg vitamin B(12))” PMID 22554931 ↗ May 2012 “high-dose folate (folic acid), B6, and B12 supplementation” NCT00056225 ↗ “50 mcg cyanocobalamin (B12) and biotin” NCT01474486 ↗ “Includes vitamins A, C, B12, E, and B2” NCT00116493 ↗ “Cyanocobalamin (vitamin B12) - 12 mcg” NCT07592897 ↗ “Vitamin B12 2.6 µg” NCT05426395 ↗ |
| Known as | Cyanocobalamin | “The experimental group received one tablet of Tenavit® (pyridoxine hydrochloride 4.00mg + folic acid 0.80mg + cyanocobalamin 0.40mg) daily and the placebo group received the...” NCT03221816 ↗32“Active drug comprised of: ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine, riboflavin 5' phosphate, niacinamide, pyridoxine, calcium d-pantothenate, and...” NCT04708340 ↗ “Participants received a daily capsule containing 40 mg of folic acid, 100 mg of pyridoxine hydrochloride (vitamin B6), and 2 mg of cyanocobalamin (vitamin B12) or a placebo.” PMID 17848650 ↗ Sep 2007 “Complex B ((Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg) 1 tablet enteral route every 6 horas for 4 days or until ICU discharge” NCT04197115 ↗ “Group O-oral was given 28 tablets of 1000 µg cyanocobalamin in a monthly punch card fitted with an electronic monitoring system.” PMID 28421567 ↗ Apr 2017 “Dosage: 25 mg of Dexketoprofen + Cyanocobalamin 500 µg, Thiamine 100 mg, Pyridoxine 50 mg. Administration way: oral” NCT05027126 ↗ “Celecoxib+Pregabalin+Vitamin B(thiamine mononitrate/pyridoxone hydrochloride/cyanocobalamin)+Placebo” NCT06516094 ↗ “Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day” NCT02620345 ↗ “5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day.” NCT01095211 ↗ “IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.” NCT00901394 ↗ “Vitamin B12 (Cyanocobalamin) - 500 mcg” NCT07296354 ↗ |
| Known as | hydroxocobalamin | “High-Dose IV Hydroxocobalamin (Vitamin B12) in Septic Shock: A Double-Blind, Allocation-Concealed, Placebo-Controlled Single-Center Pilot Randomized Controlled Trial (The...” PMID 36174744 ↗ Sep 2022 |
| Known as | methycobal | “Ultrasound-guided hydrodissection with 3cc Vitamin B12 (methycobal, 500μg/ml) between carpal tunnel and median nerve.” NCT03802422 ↗ |
| Known as | Nascobal | “Nascobal nasal spray (cyanocobalamin, USP)” NCT01306123 ↗ |
| Known as | Vitarubin-superconc | “Vitamin B12 (Vitarubin®-superconc., Streuli Pharma AG, Uznach) 1 mg sc.” NCT02031289 ↗ |
| Action | Inhibit | “homocysteine levels can be reduced by administration of high dose supplements of folate (folic acid) and vitamins B6 and B12” NCT00056225 ↗ |
| Modality | Other / unclassified | “an adjunctive B-vitamin supplement” PMID 30771856 ↗ Jan 2019 |
| Route | Oral | “Participants will be randomly assigned to receive three capsules of either vitamin B12 or placebo daily.” NCT00120484 ↗ |